Cheng Lu/AoF costs

Alternative splicing has been shown to play important roles in cancer development. Currently, most alternative splicing studies stay on bulk RNA-seq level. Although it is estimated that 92% of human genes undergo alternative splicing, studies using bulk RNA-seq can only uncover alternative splicing for a small proportion of genes in cancer. This is due to the heterogeneous nature of cancer, in which significant splicing events specific for a cell population are averaged out over all heterogenous cells. Therefore, it is natural to resort to single cell RNA sequencing (scRNA-seq) to handle the heterogeneity in cancer. In this project, I will use a multi-omics approach to systematically study alternative splicing and its regulation from scRNA-seq of cancer.